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SUMMARY
Persistent activation of Stat3 is oncogenic and is prevalent in a wide variety of human cancers. Chronic cyto-
kine stimulation is associatedwith Stat3 activation in some tumors, implicating cytokine receptor-associated
Jak family kinases. Using Jak2 inhibitors, we demonstrate a central role of Jaks inmodulating basal and cyto-
kine-induced Stat3 activation in human solid tumor cell lines. Inhibition of Jak2 activity is associated with
abrogation of Stat3 nuclear translocation and tumorigenesis. The Jak2 inhibitor AZD1480 suppresses the
growth of human solid tumor xenografts harboring persistent Stat3 activity. We demonstrate the essential
role of Stat3 downstream of Jaks by inhibition of tumor growth using short hairpin RNA targeting Stat3.
Our data support a key role of Jak kinase activity in Stat3-dependent tumorigenesis.INTRODUCTION
The signal transducer and activator of transcription (Stat)
proteins comprise a family of transcription factors that mediate
cytokine and growth factor responses (Akira et al., 1994; Darnell,
1997; Darnell et al., 1994). Persistent activation of Stat3 is onco-
genic (Yu and Jove, 2004) and is prevalent in a wide variety of
human cancers, including breast, prostate, head and neck,
and ovarian cancers, among other solid and hematologic tumors
(Bromberg et al., 1999; Catlett-Falcone et al., 1999; Dhir et al.,
2002; Garcia et al., 2001; Grandis et al., 2000; Levy and Inghir-
ami, 2006; Silver et al., 2004; Yu et al., 2007). Aberrant Stat3
activation is required for the survival of some types of human
cancer cells by promoting the overexpression of genes that
encode antiapoptotic proteins, cell-cycle regulators, and angio-
genic factors (Bowman et al., 2000, 2001; Grandis et al., 2000;
Niu et al., 2002b).
Stat3 is activated by phosphorylation of Tyr705, promoting
cytosolic dimerization, nuclear translocation, and DNA bindingC(Darnell et al., 1994). Stat activation by cytokines is mediated
through the Janus family kinases (Jak), which include four family
members, Jak1, Jak2, Jak3, and Tyk2 (Schindler and Darnell,
1995). Jak1, Jak2, and Tyk2 are ubiquitously expressed,
whereas expression of Jak3 is primarily restricted to the
lymphoid lineage (Johnston et al., 1994). Jak family kinases
associate with the large hematopoietin subfamily of cytokine
receptors that lack intrinsic kinase activity and are dependent
on Jak catalytic activity for signal transduction (Leaman et al.,
1996). In addition, Stat3 can be phosphorylated by activated
growth factor receptors such as c-MET and EGFR (Boccaccio
et al., 1998; Quesnelle et al., 2007). Src family kinases have
also been implicated in Stat3 activation (Bowman et al., 2000).
A growing body of evidence has documented an important
role for autocrine and/or paracrine cytokine loops in driving
aberrant activation of Stat3 in human cancer. In particular, inter-
leukin-6 (IL-6) signaling has been implicated in tumorigenesis
(Catlett-Falcone et al., 1999; Grivennikov et al., 2009; Hodge
et al., 2005; Hong et al., 2007). Recent studies in breast (BerishajSIGNIFICANCE
Development of small molecule inhibitors of Jak2 for the treatment ofmyeloproliferative neoplasms provides an opportunity
to assess the role of persistent Jak/Stat activation in solid tumors. Chronic cytokine stimulation is associated with consti-
tutive Stat3 activation in many types of tumors, contributing to growth and survival. Using the Jak2 inhibitor AZD1480, we
demonstrate the central role of Jak family kinases in Stat3 activation and growth of human solid tumor xenografts. Our data
provide support for the further development of Jak2 inhibitors for treatment of solid tumors.ancer Cell 16, 487–497, December 8, 2009 ª2009 Elsevier Inc. 487
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Jak/Stat Inhibition in Human Tumor CellsFigure 1. Janus Kinase Family Selectivity of
AZD1480
Jak family kinase selectivity was determined using
both enzymatic assays and Ba/F3 cells engi-
neered to express constitutively active Jak
kinases by fusing the kinase domain of Jak1,
Jak2, Jak3, and Tyk2 with the dimerization domain
of TEL.
(A) Chemical structure of AZD1480.
(B) Jak1, Jak2, and Jak3 enzymatic assays were
carried out in triplicate at Km levels of ATP and 5
mM ATP. Ranges depicted represent ± SD.
(C) Inhibition of Stat5 phosphorylation in Ba/F3
TEL-Jak2, TEL-Jak3, TEL-Jak1, and TEL-Tyk2
cells. TEL-Jak cells were treated with the indi-
cated concentrations of AZD1480 for 1 hr and
the levels of phospho-Stat5 were determined by
western immunoblotting. Signal intensity was
quantified using Li-Cor Odyssey software. IC50
values were calculated from a minimum of
three independent experiments. Ranges depicted
represent ± SD.
(D) Inhibition of Jak1, Jak2, Jak3, and Tyk2 kinase-driven cellular proliferation in engineered Ba/F3 cell lines. TEL-Jak cells were plated in 96-well plates, treated
24 hr later with AZD1480, and incubated for 48 hr. Cell proliferation was determined using the Alamar blue assay. GI50 values were calculated from a minimum of
four independent experiments. Ranges depicted represent ± SD.et al., 2007), lung (Gao et al., 2007), and diffuse large B cell
lymphoma (Lam et al., 2008) cancer cell lines have demonstrated
a central role of Jak family kinases in mediating IL-6 signaling in
these cells. These observations provide a molecular basis for
constitutive Stat3 activation in solid tumor types and highlights
Jaks as potential targets for cancer therapy.
The recent identification of an acquired Jak2 mutation in
myeloproliferative neoplasms has led to the rapid development
of selective Jak2 small-molecule inhibitors (Levine and Gilliland,
2008; Morgan and Gilliland, 2008). These reagents provide
a means of testing the involvement of Jaks in Stat3-dependent
tumorigenesis. We have used the Jak2 inhibitors AZ960 (Gozgit
et al., 2008) and AZD1480 to determine whether Jak2 is a central
mediator of constitutive and inducible Stat3 activation in tumor
cells and if inhibition of this signaling axis could suppress the
growth of solid tumor xenografts.
RESULTS
In Vitro Characterization of AZD1480
The pyrazolyl pyrimidine AZD1480 is a potent ATP competitive
inhibitor of Jak2 kinase, with an inhibition constant (Ki) of
0.26 nM (Figure 1A and Figure S1 available online). To evaluate
Jak family selectivity of AZD1480, we carried out Jak1, Jak2,
and Jak3 enzymatic assays at Km levels of ATP and 5 mM
ATP, the high end of ATP concentrations in cells (Figure 1B).
AZD1480 demonstrated significant Jak2 selectivity over Jak3,
in particular at high ATP concentrations and marginal selectivity
over Jak1 at Km ATP.
To evaluate the cellular selectivity of AZD1480 between the
Jak family of kinases, we tested a panel of isogenic Ba/F3 cell
lines driven by the JH1 catalytic domains of Jak1, Jak2, Jak3,
or Tyk2 fused to the oligomerization domain of TEL (Gozgit
et al., 2008; Lacronique et al., 2000). AZD1480 inhibited the
phosphorylation of Stat5 with an IC50 of 46 nM in TEL-Jak2 cells,488 Cancer Cell 16, 487–497, December 8, 2009 ª2009 Elsevier Inc.whereas little or no inhibition of Stat5 phosphorylation was
observed in the TEL-Jak3, TEL-Jak1, or TEL-Tyk2 cells at or
below 1 mM AZD1480 (Figure 1C). In these same cells, AZD1480
potently inhibited the growth of the TEL-Jak2 cell line with a GI50
of 60 nM. Proliferation of Ba/F3 cell lines bearing the other Jak
family members was inhibited at much higher GI50 values in
line with the selectivity observed in enzyme and/or pStat5 assays
(Figure 1D).
To assess the overall kinase selectivity, we evaluated
AZD1480 against a panel of 82 kinases (Millipore Corporation)
at or near Km for ATP with three drug concentrations (0.01,
0.10, and 1.0 mM). The kinases represent the diversity of the
kinome based on kinase binding site similarity and the gate-
keeper residue, a major determinant of small molecule kinase
selectivity. Eleven out of 82 kinases, including Jak2, were
inhibited by greater than 50% at 0.10 mM (Figure S2).
Jaks Are Central Mediators of Stat3 Signaling in Solid
Tumor Cells
Screening of a panel of cell lines manifesting constitutive or
inducible Stat3 tyrosyl phosphorylation demonstrated that in
virtually all (17/18) of the lines pStat3Tyr705 was dependent on
Jak kinase activity (Figures 2A and 2B). Stat3 is activated
downstream of Src family kinases and activated growth factor
receptors, therefore the impact of Src, EGFR, and Met kinase
inhibitors was also tested. Notably, neither inhibition of Src
(15 cell lines tested) nor EGFR (seven cell lines tested) resulted
in modulation of pStat3Tyr705 in this panel of cell lines, despite
complete inhibition of pSrc and pEGFR (Figure S3). Only c-Met
inhibition in the gastric cell line MKN45 showed Jak2-indepen-
dent inhibition of pStat3Tyr705. These data indicate a central
role of Jak family kinases in mediating Stat3 activation in solid
tumor cell lines.
To further investigate the role of Jak kinases in modulating
Stat3 activity, we used a murine embryonic fibroblast (MEF) cell
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Jak/Stat Inhibition in Human Tumor Cellsline lacking endogenous Stat3 expression and stably express-
ing a yellow fluorescent protein (YFP)-Stat3 fusion protein
(MEF-Stat3-YFP). AZD1480 inhibited Jak2 autophosphorylation
in MEF-Stat3-YFP cells when stimulated with oncostatin M
(OSM), a member of the IL-6 cytokine family (Hintzen et al.,
2008) (Figure 3A). Jak1 activity was also assessed as it is
involved in IL-6-stimulated Stat3 activity (Guschin et al., 1995).
AZD1480 had no effect on Jak1 autophosphorylation at doses
Figure 2. Jak Kinase Inhibition Blocks Stat3
Phosphorylation in a Panel of Human Solid
Tumor Cell Lines
Cells were treated with either DMSO (V, vehicle
control, 0.01%), Jak2 inhibitor AZ960 (0.3 mM),
Src inhibitor Dasatinib (0.3 mM), EGFR inhibitor
Gefitinib (1.0 mM), or Met inhibitor PF-2341066
(0.3 mM) for 1 hr and cell lysates were probed for
pStat3Tyr705 and Stat3 by western blotting.
(A) Representative immunoblots showing de-
creased pStat3Tyr705 in cells treated with a Jak2
inhibitor. Hep3B cells were either stimulated with
IL-6 (10 ng/ml) for 30 min or pretreated with the
indicated inhibitor for 30 min and then cotreated
with IL-6 for an additional 30 min.
(B) Color-coded table of cell lines screened for
Stat3 phosphorylation. Drug treatments that
resulted in a decrease in Stat3 phosphorylation
are shown in green and those which did not modu-
late pStat3 are shown in red.
Figure 3. Inhibition of Jak2 Blocks Nuclear
Translocation of Stat3
(A) Inhibition of OSM-stimulated Stat3 phosphory-
lation. Western blot of whole-cell lysates pre-
pared from OSM-stimulated MEF-Stat3-YFP cells
treated with the indicated concentrations of
AZD1480. Cells were pretreated with AZD1480
for 2 hr, and were then stimulated with 25 ng/ml
OSM for 30 min.
(B) Inhibition of Stat3 nuclear translocation. OSM-
stimulated MEF-Stat3-YFP cells were treated with
the indicated concentrations of AZD1480 and then
were stained with DAPI and visualized by confocal
microscopy. Blue depicts the nucleus and yellow
depicts localization of Stat3 protein. Scale bars
represent 10 mm.
(C) Quantification of nuclear translocation of Stat3
of the images in (B); the method is described in
the text. Error bars represent SD among the data
obtained from five cells in each cohort of the
experiment outlined in (B).
required to inhibit Stat3 phosphorylation
(0.5 mM; Figure 3A). Dose-dependent
inhibition of Stat3 nuclear translocation
was detected with confocal microscopy
(Figure 3B) that correlated with inhibition
of Jak2 and Stat3 phosphorylation
(Figure 3A). The images obtained from
confocal microscopy were quantified as
described in Experimental Procedures,
revealing an IC50 for the inhibition of Stat3 nuclear translocation
of 350 nM (Figure 3C).
Jak2 Contributes to Stat3-Mediated Oncogenesis
MEF-Stat3-YFP cells were used as a model of Stat3-mediated
oncogenesis to address whether Jak2 inhibition can suppress
the growth of a Stat3-dependent tumor. MEF-Stat3-YFP cells
have been transformed by the Stat3-YFP fusion construct asCancer Cell 16, 487–497, December 8, 2009 ª2009 Elsevier Inc. 489
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Jak/Stat Inhibition in Human Tumor CellsFigure 4. Jak2 Inhibition Suppresses
Stat3-Mediated Tumorigenesis
(A) Expression of Stat3 promotes formation of MEF
tumors in mice. Tumor growth of MEF cells (gray
line) and MEF-Stat3-YFP cells (black line). Results
presented as mean tumor volume (n = 8), error
bars represent standard error, and the p value
(Student’s t test) at day 15 is indicated.
(B) Treatment of MEF-Stat3-YFP tumor-bearing
mice once daily with 50 mg/kg of AZD1480 (orally)
(black line) or vehicle-treated control (gray line).
Mice were dosed on a repeating schedule of five
continuous days of once daily dosing, followed
by 2 days of rest, for 24 days. The arrow indicates
initiation of treatment. Results are presented as
mean tumor volume (n = 6), error bars represent
standard error, and p value (Student’s t test) at
day 33 is indicated.
(C) AZD1480 inhibits pStat3 activity in MEF-Stat3-
YFP tumors. Western blot of tumors following the
efficacy study outlined in (B) is shown. Tumors
were harvested 2 hr after treatment.
(D) Intravital multiphoton laser microscopy of Stat3
subcellular localization in a tumor. Two photon
imaging of intact MEF-Stat3-YFP tumors treated
with AZD1480 at 50 mg/kg for 2 weeks, as
described above, or with vehicle alone. Tumors
were visualized 2 hr after treatment. Stat3 was visualized in real time through exciting the YFP fluorophore tethered to the Stat3 protein. Individual fluorescence
channels are presented in the vehicle-treated and AZD1480-treated tumors. Merged images in the control tumor display nuclear localization of Stat3 as depicted
by the white dots in the field, created by an overlap of the nuclei and Stat3 emissions. Merged images of the treated tumor depict areas of Stat3 fluorescence that
do not overlap with nuclei fluorescence, indicating cytoplasmic localization of Stat3. Scale bars represents 100 mM.evidenced by their ability to form tumors following subcutaneous
implantation in athymic mice, whereas the parental Stat3/
MEF cells were unable to grow in vivo (Figure 4A). After once
daily treatment of tumor-bearing mice with 50 mg/kg AZD1480
(orally), the growth of MEF-Stat3-YFP tumors were inhibited
58% (p = 0.001, n = 6) relative to the vehicle-treated control
cohort (Figure 4B).
Stat3 tyrosyl phosphorylation was determined in lysates
derived from tumors 2 hr after treatment with AZD1480. Although
constitutive Stat3 activity was found in the vehicle-treated
tumors, pStat3Tyr705 was abolished in tumors that were treated
with AZD1480 (Figure 4C). Constitutive phosphorylation of
Stat3 in the xenograft setting, but not under routine cell culture
conditions (Figure 3A), indicates activation of the pathway likely
by the tumor microenvironment.
Intravital multiphoton laser microscopy was performed on
mice bearing MEF-Stat3-YFP tumors to visualize Stat3 subcel-
lular localization in the tumors. MEF-Stat3-YFP tumors were
found to have a predominance of nuclear-localized Stat3 coin-
ciding with the constitutive expression of pStat3Tyr705 observed
by western blotting (Figure 4D). Treatment of MEF-Stat3-YFP
tumors with AZD1480 resulted in inhibition of Stat3 nuclear
translocation in vivo, correlating with the inhibition of pStat3Tyr705
observed after treatment with AZD1480 (Figure 4D).
Jak2 Mediates IL-6-Dependent Survival of Androgen-
Independent Prostate Cancer Cells
The LnCaP subline LN-17 expresses constitutive Stat3 activity
as a consequence of stable expression of an exogenous IL-6
gene and endogenous expression of the IL-6R (Lee et al.,
2003; Lou et al., 2000). The resulting IL-6 autocrine loop allows490 Cancer Cell 16, 487–497, December 8, 2009 ª2009 Elsevier Inc.LN-17 cells to survive under androgen deprivation conditions.
LN-17 cells were treated with AZD1480 to determine whether
Jak2 blockade can abrogate IL-6-dependent survival. Dose-
dependent inhibition of pStat3Tyr705 (Figure 5A) and Stat3
DNA binding activity (Figure 5B) was observed in response to
the addition of AZD1480, as was a loss of viability (Figure 5C).
The loss of viability was associated with a dose-dependent
increase in the apoptotic markers Annexin V (Figure 5D) and
PARP cleavage (85 kDa fragment) (Figure 5E). To confirm the
Jak2 dependency of Stat3 signaling in these cells, we tested
the effect of two siRNAs directed against Jak2 to determine
whether they could inhibit Stat3 tyrosine phosphorylation.
Reduction of Jak2 protein expression by siRNAs 1 and 2
inhibited Stat3 signaling compared to a nonsilencing control
siRNA (Figure 5F).
AZD1480 Suppresses the Growth of Tumors
with Constitutive Stat3 Activity
The LN-17 subline was incapable of growth in mice, thus we were
unable to assess the in vivo efficacy of Jak2 inhibition in this
model. To determine whether AZD1480 could impact the growth
of human tumors, we turned to solid tumor xenograft lines that
displayed constitutive Stat3 activation and an IL-6 autocrine
loop. The cancer cell lines DU145 (prostate), MDAH2774
(ovarian), and MDA-MB-468 (breast) were chosen. DU145 and
MDA-MB-468 express IL-6 autocrine loops (Berishaj et al.,
2007; Okamoto et al., 1997), and we have determined
that MDAH2774 cells both secrete IL-6 and express IL-6R
(Figure 6A). Constitutive pStat3Tyr705 was inhibited in a dose-
dependent manner by AZD1480 in all three cell lines (Figure 6B).
Significant inhibition of pStat3Tyr705 is observed at 0.1 mM drug
Cancer Cell
Jak/Stat Inhibition in Human Tumor CellsFigure 5. Jak2 Mediates IL-6-Dependent
Survival in Human Prostate Cancer Cells
(A) Stat3 activity was assayed by western blotting
in LN-17 cells treated for 24 hr with the indicated
concentrations of AZD1480.
(B) EMSA to visualize Stat3 DNA binding after
treatment with a Jak2 inhibitor. LN-17 cells were
treated as in (A) and EMSA was performed to
monitor Stat3 homodimer DNA binding activity.
The first lane is the control-treated sample incu-
bated with a Stat3 blocking antibody to confirm
Stat3 binding.
(C) Cell viability was assayed with an MTS assay
72 hr after treatment with the indicated concentra-
tions of AZD1480. Error bars represent the SD
of three experiments conducted independently.
p < 0.02, *p < 0.01.
(D) Flow cytometric analysis of LN-17 cells stained
with Annexin V 72 hr after treatment with the
indicated concentrations of AZD1480. Error
bars represent the SD among triplicate samples.
*p < 0.01.
(E) Apoptosis was assayed by western blot with an
antibody against the cleaved 85 kDa PARP frag-
ment in LN-17 cells treated with the indicated
concentrations of AZD1480 for 72 hr.
(F) Two siRNAs (300 nM) targeting Jak2 were
transfected with the Amaxa Nucleofector system
and were harvested 48 hr later. Cell lysates were
immunoblotted with indicated antibodies. A nonsi-
lencing (NS) siRNA was used as a negative control.and near ablation of signal is observed at 0.25–0.5 mM. These cell
lines show greater sensitivity to inhibition of Stat3 phosphoryla-
tion by AZD1480 than does the MEF-Stat3-YFP line (Figure 3A),
perhaps reflecting Stat3 overexpression in the transfected MEF
cells. In all three lines, exogenous addition of IL-6 induced phos-
phorylation of Stat3Tyr705 (Figure 6C), which was inhibited
following treatment with AZD1480.
We transfected siRNAs directed against Jak1, Jak2, and Tyk2
to identify the Jak family kinase primarily responsible for Stat3
activation in MDAH2774 cells. While we observed successful
inhibition of Jak1, Jak2, and Tyk2 protein expression with the
siRNAs, only reduction of Jak1 protein suppressed Stat3 phos-
phorylation compared to the GAPDH negative control siRNA
(Figure 6D).
AZD1480 did not inhibit in vitro growth of DU145, MDAH2774,
and MDA-MB-468 cells at doses that abrogated Stat3 tyrosyl
phosphorylation (data not shown). In a 72 hr viability assay,
GI50 values for the three lines ranged from 2.4 to 5.4 mM, indi-
cating that under standard cell culture conditions, Jak2/Stat3
signaling was not essential for survival and growth inhibition
probably reflects off-target activities manifested at the high
drug levels. Similar observations are made for the panel of solid
tumor cell lines shown in Figure 1B. To assess the impact of Jak
inhibition on in vivo tumor growth, we treated mice bearing
DU145 and MDA-MB-468 tumors once daily with AZD1480. In
this context, AZD1480 demonstrated significant tumor growth
inhibition of DU145 (81% growth inhibition, p < 0.001, n = 7)
and MDA-MB-468 (111% growth inhibition, p < 0.001, n = 7)
xenografts, relative to vehicle-treated cohorts (Figure 7A).
An alternative dosing schedule and dose levels were tested in
mice bearing MDAH2774 xenografts. Tumor-bearing mice wereCtreated with 1, 10, and 30 mg/kg AZD1480 twice daily. A dose-
dependent reduction in tumor growth was observed, with
comparable tumor growth inhibition observed at 10 mg/kg twice
daily (71% growth inhibition, p < 0.001, n = 10) to that observed
at 50 mg/kg once daily. Upon twice daily dosing with 30 mg/kg
AZD1480 (Figure 7A), tumor regression was observed (139%
growth inhibition, p < 0.001, n = 10). No lethal toxicity or weight
loss was observed at the doses of AZD1480 spanning 26 days of
dosing (Figure S4). Given the well established role of Jak family
kinases in hematopoiesis, and particularly of Jak2 in erythropoi-
esis, we evaluated red and white blood cell counts in mice
treated with AZD1480. No significant changes in white blood
cell counts occurred after 10 days of treatment at 10 or 30 mg/kg
twice daily. Over the same time period red blood cell counts
decreased approximately 13% in response to 30 mg/kg twice
daily AZD1480, while no changes were observed at 10 mg/kg
twice a day (Figure S5).
Tumor Growth Inhibition Correlates with Inhibition
of Constitutive Stat3 Signaling
Complete inhibition of pStat3Tyr705 was observed in tumor
lysates prepared from xenografts harvested 2 hr after
AZD1480 treatment (Figure 7B). More detailed kinetic analysis
of tumor lysates from MDAH2774 xenograft-bearing mice 2, 6,
10, and 16 hr after a single 30 mg/kg dose of AZD1480 demon-
strated that expression of pStat3Tyr705 begins to recover by
6–10 hr after drug treatment and appears to be fully recovered
by 16 hr (Figure 7B). Immunohistochemical analysis of tumor
sections demonstrated that pStat3Tyr705, and its inhibition by
AZD1480, was evident not only in tumor cells but also in adjacent
mouse tumor stroma (Figure S6).ancer Cell 16, 487–497, December 8, 2009 ª2009 Elsevier Inc. 491
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Jak/Stat Inhibition in Human Tumor CellsFigure 6. Jak Kinase Inhibition Abrogates
IL-6-Induced and Constitutive Stat3 Activity
of Human Cancer Cells
(A) MDAH2774 cells express IL-6 and IL-6R.
Culture medium and cell lysates were collected
from MDAH2774 cells after 1, 2, and 3 days of
culture, and tumor lysates were collected from
mice bearing MDAH2774 xenografts (n = 7).
Human IL-6 was measured by Luminex Immuno-
assay using the Milliplex cytokine kit (Millipore).
For culture medium and cell lysate, error bars
denote the SD for each sample measured in dupli-
cate. For tumor lysate, samples were measured in
triplicate and the error bar denotes the SD of the
mean measurements. IL-6R was assayed in three
individual tumor lysates by western blotting.
(B) AZD1480 inhibits constitutive Stat3 activity in
human cancer cells. Western blotting of whole-
cell lysates of DU145, MDA-MB-468, and
MDAH2774 cells prepared 2 hr after treatment
with the indicated concentrations of AZD1480 is
shown.
(C) Western blot analysis of whole cell lysates
prepared from DU145, MDA-MB-468, and
MDAH2774 cells that were starved in 5% CS-
FBS for 18 hr (DU145 and MDA-MB-468) or serum
starved for 3 hr (MDAH2774), and then treated with
the indicated concentrations of AZD1480 for 2 hr.
Cells were then stimulated with 10 ng/ml IL-6 for
15 min after pretreatment with AZD1480.
(D) Jak1 siRNA blocks phosphorylation of Stat3
in MDAH2774 cells. Jak1-siRNAs, Jak2-siRNAs,
or Tyk2-siRNAs (100 nM) were transfected into MDAH2774 cells using the Amaxa Nucleofector system and were harvested 24 and 48 hr later.
Cell lysates were immunoblotted with indicated antibodies. GAPDH siRNA was used as a negative control.IL-6 can also stimulate the ERK and PI3K pathways (Culig
et al., 2005); therefore, we examined whether Jak inhibition
was modulating these signaling pathways. No significant change
in expression of p44/42 pMAPK and pAKTSer473 was detected in492 Cancer Cell 16, 487–497, December 8, 2009 ª2009 Elsevier Inctumors treated with AZD1480 compared to control animals
(Figure 7B). Furthermore, since AZD1480 inhibited Aurora A
enzyme activity in the kinase panel (Figure S2), xenograft tumor
sections were examined for evidence of mitotic block, theFigure 7. AZD1480 Suppresses the Growth
of Human Xenograft Tumors Harboring
Constitutive Stat3 Activity
(A) DU145 and MDA-MB-468 tumor-bearing mice
were treated once daily with AZD1480 (black line)
at 50 mg/kg (orally) or vehicle (gray line) for 5 days,
followed by 2 days of rest, over a total course of
treatment of 26 days (DU145) or 30 days (MDA-
MB-468). The arrow indicates initiation of treat-
ment. Results are presented as mean tumor
volume (n = 7), bars indicate standard error, and
p value (Student’s t test) at day 37 (DU145) or
day 57 (MDA-MB-468) is indicated. As shown
on the bottom, MDAH2774-bearing mice were
treated twice daily with 1, 10, and 30 mg/kg (orally)
for 26 consecutive days. The arrow indicates initi-
ation of therapy. Results presented as mean tumor
volume, bars indicate standard error, and p value
(Student’s t test) at day 44 is indicated.
(B) Western blot analysis of tumors 2 hr after treat-
ment with AZD1480. DU145 tumors were obtained
after 26 days of treatment with 50 mg/kg
AZD1480, MDA-MB-468 tumors were obtained
after 30 days of treatment with 50 mg/kg
AZD1480, and MDAH2774 tumors were exposed
to only a single dose of 30 mg/kg AZD1480..
Cancer Cell
Jak/Stat Inhibition in Human Tumor Cellsphenotypic endpoint of Aurora A inhibition (Manfredi et al., 2007),
by staining for the mitotic marker pHisH3. No modulation of
pHisH3 staining was observed in MDAH2774 xenografts treated
with 30 mg/kg AZD1480 for up to 16 hr after the dose was given
(Figure S7).
To confirm that suppression of tumor growth observed upon
AZD1480 treatment was due to inhibition of Stat3 signaling, we
created MDA-MB-468 cells stably expressing either Stat3
shRNA or vector alone. MDA-MB-468 cells expressing Stat3
shRNA displayed significant decreases in both total Stat3 and
pStat3Tyr705 in culture compared to empty vector or non-
silencing control shRNA-expressing cells (Figures 8A and 8C).
In vitro evaluation of the stably infected MDA-MB-468 cells
revealed no significant change in the growth of Stat3 shRNA-
expressing compared to empty vector cells (data not shown).
However, the growth of MDA-MB-468 tumors expressing Stat3
shRNAs were significantly impaired compared to tumors
expressing the empty vector or non-silencing shRNA (Figures
8B and 8D).
The converse experiment to inhibiting Stat3 expression is
overexpression of an activated Stat3 mutant whose activity is
independent of tyrosine phosphorylation. To confirm that tumor
growth inhibition observed upon treatment with AZD1480
was due to inhibition of Stat3 signaling, we tested whether
AZD1480 could inhibit the growth of 786-0 renal cell carcinoma
xenografts expressing a constitutively active Stat3 mutant,
Stat3C (Bromberg et al., 1999). While 786-0 xenografts express-
ing Stat3C exhibited no growth inhibition, the growth of vector
control xenografts were inhibited following 41 days of treatment
with 50 mg/kg AZD1480 when compared to vehicle-treated
xenografts (48% growth inhibition, p = 0.038, n = 10) (Figure S8).
Figure 8. Expression of Stat3 shRNA
Inhibits theGrowth of HumanBreast Cancer
Cells
(A) Western blot of whole-cell lysates derived from
MDA-MB-468 cells grown in culture expressing
Stat3 shRNA1 or vector alone.
(B) Reduction of Stat3 expression results in inhibi-
tion of MDA-MB-468 tumor growth. The growth of
MDA-MB-468 subcutaneous xenografts express-
ing either Stat3 shRNA1 or vector alone control
were monitored for 58 days. Results are presented
as mean tumor volume (n = 6) with standard error,
and p value (Student’s t test) at day 58 is indicated.
(C) Western blot of whole-cell lysates derived from
MDA-MB-468 cells grown in culture expressing
Stat3 shRNA2 or nonsilencing (NS) control shRNA.
(D) The growth of MDA-MB-468 subcutaneous
xenografts expressing either Stat3 shRNA2 or
nonsilencing shRNA were monitored for 56 days.
Results are presented as mean tumor volume
(n = 6) with standard error, and p value (Student’s
t test) at day 56 is indicated.
Moreover, decreased apoptosis was
observed after treatment with AZD1480
in Stat3C-expressing xenografts com-
pared to treated control cells (Figure S8).
These data provide further evidence that
tumor growth inhibition by AZD1480 is due at least in part to
inhibition of Stat3 signaling.
DISCUSSION
Persistent Stat3 activation is prevalent in many types of human
cancers and contributes to tumor progression. While direct
inhibition of transcription factors with small-molecule inhibitors
has proven challenging, targeting of upstream activating kinases
offers a pharmaceutically viable alternative. The mechanism of
persistent Stat3 activation in cancer tissues and cell lines has
been attributed to phosphorylation by Jak and Src family
kinases, as well as activated receptor tyrosine kinases including
EGFR (Boccaccio et al., 1998; Bowman et al., 2000; Lo et al.,
2007; Quesnelle et al., 2007). The availability of Jak2 inhibitors
such as AZD1480 makes it possible to test the impact of Jak
inhibition on Stat3 activation in solid tumor cell lines. In a panel
of cell lines displaying constitutive Stat3 activation, we found
that almost all cell lines were dependent on Jak kinase activity
for Stat3 activation.
In none of the cell lines tested was tyrosyl phosphorylation of
Stat3 suppressed by inhibition of Src activity, and in only one cell
line was Stat3 found to be phosphorylated downstream of
a receptor tyrosine kinase, in this case c-Met. While previous
reports have indicated a role for Src family kinases and growth
factor receptors such as EGFR in phosphorylation of Stat3, it is
likely that these receptor and non-receptor tyrosine kinases
cooperate with Jak family kinases to activate Stat3 (Gao et al.,
2007; Garcia et al., 2001; Niu et al., 2002a; Wang et al., 2000;
Xi et al., 2003). Thus, depending on the cellular context, other
non-receptor and receptor tyrosine kinases may indirectlyCancer Cell 16, 487–497, December 8, 2009 ª2009 Elsevier Inc. 493
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demonstrate that Jak family kinases are essential for Stat3 acti-
vation. These observations indicate that Jak-mediated phos-
phorylation and activation of Stat3 is a common mechanism in
a majority of human cancer cell lines.
Inhibition of Stat3 phosphorylation by AZD1480 in MEF-Stat3-
YFP cells correlates with dose-dependent inhibition of Stat3
nuclear translocation and Stat3-dependent tumor growth.
Reconstitution of Stat3 expression in MEF cells resulted in tumor
growth, in contrast to the parental Stat3 null cells, confirming the
essential role of Stat3 in this tumor model. In vivo activation of
Stat3 appears to be primarily mediated by Jak2, since treatment
of tumor-bearing mice with AZD1480 resulted in inhibition of
Stat3 activation and tumor growth. We also demonstrate Stat3
subcellular localization in MEF-Stat3-YFP tumors by intravital
multiphoton laser microscopy.
In cancer cell lines and tissues, there is evidence for constitu-
tive activation of Stat3 through chronic cytokine stimulation upon
the establishment of autocrine or paracrine loops, often involving
IL-6 (Culig et al., 2005; Grivennikov and Karin, 2008; Rabinovich
et al., 2007). The IL-6R shares the common gp130 subunit that
signals through receptor-associated Jak family kinases. We
have shown, in multiple cell lines, that IL-6-driven stimulation
of Stat3 tyrosyl phosphorylation can be completely blocked
by AZD1480. IL-6 is known to signal through Jak1, Jak2, and
Tyk2, with Jak1 reported to play an essential role (Guschin et al.,
1995). We observed only slight inhibition of pJak1Tyr1007/1008 at
drug concentrations sufficient to inhibit pStat3Tyr705 in MEF-
STAT3-YFP cells stimulated by the IL-6 family cytokine OSM.
However, given the comparable potency of AZD1480 for Jak1
at high ATP concentrations in vitro, and that siRNA targeting
Jak1 led to a reduction of Stat3 activity in tumor cells, we cannot
rule out the possibility that inhibition of pStat3Tyr705 might be
dependent on inhibition of both Jak1 and Jak2 activity.
DU145, MDA-MB-468, and MDAH2774 express IL-6 auto-
crine loops (Berishaj et al., 2007; Okamoto et al., 1997) and their
tumorigenesis was inhibited upon treatment with AZD1480. After
once daily treatment with 50 mg/kg AZD1480, growth of DU145
and MDA-MB-468 xenografts were inhibited. Comparable tumor
growth inhibition was seen in MDAH2774 xenografts dosed
twice daily at 10 mg/kg. Increasing the twice-daily dosing level
to 30 mg/kg resulted in tumor regression. We found Jak inhibition
to be well tolerated at the doses and schedules described.
However, given the role of Jak family kinases in hematopoiesis,
more prolonged or intensive treatment may require optimization
of dose and/or schedule to achieve efficacy with manageable
impact on hematopoiesis.
Pharmacodynamic analysis of Stat3 phosphorylation demon-
strated significant inhibition of pStat3 for >10 hr after a single
dose of 30 mg/kg AZD1480. Coupled with the anti-tumor efficacy
data, this suggests that optimal tumor growth inhibition corre-
lates with sustained Stat3 pathway signaling inhibition over a
24 hr period. Reduction of Stat3 expression with shRNA in
MDA-MB-468 xenografts significantly inhibited tumor growth.
Introduction of a constitutively active Stat3C mutant into 786-0
xenografts caused these tumors to become resistant to AZD1480
treatment. These findings further support the conclusion that
tumor growth inhibition observed upon treatment with AZD1480
is dependent at least in part on inhibition of Stat3 signaling.494 Cancer Cell 16, 487–497, December 8, 2009 ª2009 Elsevier IncNotably, no inhibition of growth was observed in cell culture
for any of the xenograft cell lines at doses of AZD1480 that
maximally inhibited Stat3 phosphorylation. In addition, shRNA-
mediated knockdown of Stat3 did not significantly affect the
growth of MDA-MB-468 cells in vitro. One possibility for this
discrepancy is that Jak/Stat signaling is not required for growth
in standard two-dimensional cell culture in which cells are
exposed to the multitude of growth factors present in serum. In
the in vivo setting, the increased complexity of the tumor micro-
environment could provide a context in which Jak/Stat activity is
essential for survival. This could manifest as a tumor-autono-
mous dependence on Jak/Stat signaling and/or a dependence
on Jak/Stat signaling in the tumor microenvironment. Using
IHC analysis of tumor xenografts, we have demonstrated activa-
tion of Stat3 in the tumor stroma in addition to tumor cells and
inhibition of both signals following treatment with AZD1480.
These observations raise the possibility that tumor growth inhibi-
tion may be mediated, at least in part, by blockade of stromal
Stat3 activity.
Aberrant activation of Stat3 has been extensively documented
in human cancers and a preponderance of clinical and preclinical
data have supported a role for Stat3 in promoting tumorigenesis
(Yu and Jove, 2004). Evidence has more recently been provided
for chronic cytokine stimulation being a feature of some tumors
with constitutive Stat3 phosphorylation, providing a mechanistic
rationale for pathway activation (Grivennikov and Karin, 2008).
It remains to be determined why Stat3 activation in tumor
cells is not subject to the negative feedback regulation present
in normal cells. The role of Jak family kinases as the catalytic
subunits of cytokine receptors positions them as attractive ther-
apeutic targets for pathway inhibition. Recent development of
Jak2 inhibitors for myeloproliferative neoplasms provides the
means of testing Jak kinase as a therapeutic target in solid
tumors. Our data demonstrate that Stat3 activation is primarily
mediated by Jak kinase activity in a wide range of solid tumor
cell lines and that Jak inhibition can suppress the growth of
tumors with constitutive Stat3 activation. These data validate
Jak kinase as a molecular target in tumor indications beyond
myeloproliferative neoplasms and support the development of




AZD1480, a 4-(Pyrazol-3-ylamino) pyrimidine derivative, and AZ960 were
synthesized by AstraZeneca. Gefitinib (AstraZeneca), Dasatinib (BMS-354825;
Bristol-Myers Squibb Oncology), and PF-2341066 (Pfizer) were also used
in these studies. Stock solutions were diluted in dimethylsulfoxide (DMSO;
Sigma-Aldrich) and then diluted in culture medium for use. Anti-pStat3
(Y705), anti-Stat3, anti-Stat5, anti-pJak2 (Y1007/1008), anti-Jak2, anti-pJak1
(Y1022/1023), anti-Jak1, anti-phospho-p44/42 MAPK, anti-p44/42 MAPK,
anti-pAKT, anti-AKT, anti-pEGFR (Tyr1068), anti-pSrc family (Tyr416), anti-
GAPDH, and anti-cleaved PARP were purchased from Cell Signaling Tech-
nology. Anti-pStat5 (Tyr694) was purchased from BD Biosciences. HRP-conju-
gated anti-mouse, HRP-conjugated anti-rabbit, and HRP-conjugated anti-goat
antibodies were obtained from Cell Signaling Technology or Santa Cruz
Biotechnology. Anti-b-actin was obtained from Sigma-Aldrich. IRDye 680
goat anti-mouse and IRDye 800CW goat anti-rabbit antibodies were obtained
from Li-Cor. IL-6 and goat anti-soluble IL6-receptor antibody were purchased
from R&D Systems..
Cancer Cell
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The Ba/F3 engineered cells were generated and maintained as previously
described (Gozgit et al., 2008). MEF-Stat3-YFP cells were generated as previ-
ously described (Herrmann et al., 2004) and maintained in Dulbecco’s modi-
fied Eagle’s medium (DMEM) supplemented with 10% heat-inactivated FBS,
100 U/ml penicillin, and 0.1 mg/ml streptomycin (GIBCO). LN-17 cells (Lee
et al., 2003) (a gift from A. Gao) were maintained in RPMI-1640 supplemented
with 10% heat-inactivated FBS, 100 U/ml penicillin, 0.1 mg/ml streptomycin,
(GIBCO), and 0.4 mg/ml G418. MDA-MB-468-STAT3-shRNA cells and the
corresponding vector alone control cells were maintained in DMEM supple-
mented with 10% heat-inactivated FBS (100 U/ml) and 1.5 mg/ml puromycin.
786-0 Stat3C and vector-expressing control cells were generated as previ-
ously described (Xin et al., 2009) and maintained in RPMI-1640 supplemented
with 10% heat-inactivated FBS, 100 U/ml penicillin, 0.1 mg/ml streptomycin,
and 0.5 mg/ml G418. All other cell lines were obtained from ATCC and main-
tained according to their recommendations.
Enzyme Assays and Kinase Profiling
Inhibition studies of AZD1480 were performed using recombinant Jak1 (amino
acids 850–1154; Carna Biosciences Inc.), Jak2 (amino acids 808–1132; Milli-
pore), or Jak3 (amino acids 781–1124; AstraZeneca R&D Boston) under buffer
conditions of 50 mM HEPES (pH 7.3), 1 mM DTT, 0.01% Tween-20, 50 mg/ml
BSA, and 10 mM MgCl2. Jak3 enzyme was expressed as N-terminal GST
fusion in insect cells and purified by glutathione affinity and size-exclusion
chromatographies. Enzymes were assayed in the presence of AZD1480
(10 point dose response, in triplicate, from 8.3 mM to 0.0003 mM in half-log
dilution steps) using 1.5 mM peptide substrate (Jak1: FITC-C6-KKHTDDG
YMPMSPGVA-NH2; Intonation Technologies Inc.; Jak2 and Jak3: FAM-
SRCtide; Molecular Devices) and screened under their respective ATP Km
(Jak1: 55 mM, Jak2: 15 mM, Jak3: 3 mM) and approximated physiological
ATP concentration of 5 mM. Phosphorylated and unphosphorylated peptides
were separated and quantified by a Caliper LC3000 system (Caliper Life
Sciences) for calculating percent inhibition. Jak2 kinetic studies were per-
formed as previously described (Gozgit et al., 2008).
Viral Vector Production
293T cells were plated at a density of 43 106 cells per 10 cm culture dish. Cells
were cotransfected by calcium phosphate coprecipitation with either 15 mg of
pLKO1-Stat3 shRNA1 (#840) or pLKO1-Stat3 shRNA2 (#842) or pLK01-puro or
pLK01-non-silencing shRNA (Sigma-Aldrich) and 10 mg of pPACK packaging
plasmid mix (SBI). The culture medium was replaced with fresh medium after
6 hr. Supernatant was collected 24 and 48 hr after transfection. For deter-
mining the viral titers, 105 HT1080 cells were seeded in a six-well plate and
transduced with various dilutions of the vector in the presence of 4 mg of
Polybrene per milliliter (Sigma-Aldrich). The culture medium was replaced
48 hr later with fresh medium containing puromycin (Sigma-Aldrich) at
a concentration of 1.5 mg/ml. Puromycin-resistant colonies were counted
10 days after transduction. MDA-MD-468 cells were transduced with viral
vector at a multiplicity of infection of 0.5.
Luminex Immunoassay
IL-6 was measured with the human-specific Milliplex map kit (Millipore Corpo-
ration) in accordance with the manufacturer’s instructions and the Luminex
100 System (Bioplex System; Bio-Rad). Samples were assayed in duplicate
for cell culture medium and cell lysate and in triplicate for tumor lysate.
Total protein (mg/ml) was determined with a BCA protein assay kit (Thermo
Scientific).
Immunohistochemistry
MDAH2774 xenograft tissues were harvested 2 and 6 hr after a single
30 mg/kg dose of AZD1480, fixed in 10% neutral-buffered formalin (24 hr),
paraffin embedded, and sectioned (5 mm). Immunohistochemistry was per-
formed on the Ventana Discovery XT Autostainer using the standard CC1
protocol. Primary antibodies were pStat3 antibody (Cell Signaling Technology),
total Stat3 (Cell Signaling Technology), and pHisH3 (Cell Signaling Technology)
with either the OmniMap DAB detection kit or the DABMap detection kit.
Secondary antibody was a biotinylated anti-rabbit IgG (Vector Laboratories)
used per manufacturer’s instructions. A negative control reagent, nonimmuneCrabbit Ig (Ventana), was run in place of primary antibody to evaluate nonspecific
staining. The slides were counterstained with hematoxylin (Ventana).
Confocal Microscopy
For confocal microscopy, cells were fixed with formaldehyde as described
previously (Herrmann et al., 2004), and then mounted with Vectashield Hard-
Set mounting medium with DAPI (Vector Laboratories). Confocal imaging
was carried out on an LSM 510 Meta confocal microscope (Zeiss;
633, 1.2 NA Zeiss water immersion objective, 1 mM confocal slice). YFP emis-
sions were detected as previously described (Pranada et al., 2004). DAPI was
visualized with a two-photon laser exciting at 435–485nm.
Quantification of Stat3 Nuclear Translocation
YFP fluorescence intensity acquired by linear profiles with LSM image browser
were corrected and normalized and used for calculating a translocation index
(Ti) of Stat3 with the equation Ti = 1  (cytxmin/nucxmin) 3 (nuc0min/cyt0min),
where cyt0min and nuc0min are the average cytoplasmic and nuclear YFP fluo-
rescence, respectively, in unstimulated cells. Average cytoplasmic and
nuclear fluorescence of YFP in stimulated cells are cytxmin and nucxmin, respec-
tively. Error bars represent the SEM of five cells/cohort.
Intravital Multiphoton Laser Microscopy
Mice were maintained under specific pathogen-free conditions and were used
in compliance with protocols approved by the Institutional Animal Care and Use
Committees of City of Hope, which conform to institutional and national regu-
latory standards on experimental animal usage. Mice were anesthetized with
isofluorane gas, kept warm with either a heat lamp or a heating blanket, and
prepared for surgery. Mice were then retro-orbitally injected with 25 mg of
Hoechst 33342 (Sigma-Aldrich) and 10 mG of Annexin V-FITC (BioVision) in
Hank’s balanced salt solution. An incision was made near the midline, creating
a skin flap that exposed the tumor that was then folded over and pinned to the
cork surface of the microscope stage insert. The imaging site was cleaned with
normal saline and ddH2O and then coverslipped. The coverslip was held in
place against the tumor tissue with thumbscrews. The mouse continued to
receive isofluorane anesthesia while imaging was performed utilizing Prairie
Technologies Ultima microscope with illumination from a Coherent Chameleon
Ultra II Ti:Sapphire laser. An Olympus 103/0.3 objective lens was used and the
excitation and emission spectra used for the fluorophores were as follows:
Hoechst 33342 excitation at 730 nm with emission between 435 and 485 nm
and Annexin V-FITC and YFP excitation at 860 nm with emission between
500 and 550 nm. Extracellular matrix is given by second harmonic generation
through l[excit.] = 890 nm. TIFF-formatted images were collected using Prairie
View software at a resolution of 1024 3 1024 pixels and then transferred to
Image Pro software version 6.3 for brightness, contrast, and color adjustment.
Western Blotting
Cells were lysed with SDS buffer or RIPA buffer. Xenograft lysates were
prepared by FastPrep homogenization (MP Biomedicals) in Swedish lysis
buffer (20 mM Tris [pH 7.5], 150 mM NaCl, and 1% NP40) or RIPA buffer, sup-
plemented with 13 protease (Roche) and phosphatase (Sigma-Aldrich) inhib-
itors. 50–100 mg of protein were resolved in 4%–12% SDS-PAGE or NuPage
Novex gels (Invitrogen) and transferred to NuPage nitrocellulose membranes
(Invitrogen). After blocking (1 hr at room temperature) with 5% milk in PBS-
0.1% Tween 20, membranes were incubated overnight with indicated anti-
bodies and then exposed to secondary antibody. Immunoreactive proteins
were visualized with an enhanced chemiluminescence detection system
(Pierce Biotechnology). Signals were also detected with the Li-Cor Odyssey
Infrared system using Li-Cor blocking buffer and fluorescent Li-Cor secondary
antibodies. The westerns and quantitation described with the Ba/F3 engi-
neered cells were performed as previously described (Gozgit et al., 2008).
Cell Viability Assays
The Ba/F3 engineered cells were assayed as previously described (Gozgit
et al., 2008). Cell growth in vitro was measured using the CellTiter 96 AQ
Nonradioactive cell proliferation assay (Promega). In brief, LN-17 cells (5 3
103) were plated in 96-well plates in quintuplicate in RPMI plus 10%
charcoal-stripped FBS and allowed to attach for 24 hr prior to the addition
of DMSO or AZD1480 to the culture medium. After 72 hr, 20 ml/well ofancer Cell 16, 487–497, December 8, 2009 ª2009 Elsevier Inc. 495
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2H-tetrazolium/phenazine ethosulfate solution was added. After incubation
(1 hr, 37C, 5% CO2 atmosphere), absorbance at 490 nm was recorded by
using an ELISA plate reader.
Flow Cytometric Analysis of Annexin V
LN-17 cells (2 3 105) were seeded into six-well dishes and allowed to attach
overnight. Following attachment, the medium was replaced with RPMI con-
taining 10% charcoal-stripped FBS with DMSO, or AZD1480 as indicated.
After 72 hr incubation, cells were washed twice with cold PBS, harvested
with PBS supplemented with EDTA, and stained with the Annexin-V-FITC
apoptosis detection kit (BD Biosciences) according to the manufacturer’s
instructions. Data acquisition and analysis was performed by the Flow Cytom-
etry Core Facility at the City of Hope.
EMSA
For the detection of DNA-binding activity of Stat3 by EMSA, nuclear protein
extracts were prepared using high-salt extraction as previously described
(Garcia et al., 2001). For detection of Stat3 DNA-binding activity, 5 mg of
nuclear protein from AZD1480-treated LN-17 cells were incubated with
32P-radiolabeled double-stranded DNA oligonucleotides using a high-affinity
variant of the sis-inducible element derived from the c-fos gene promoter,
which binds activated Stat3 and Stat1 proteins (Wagner et al., 1990; Yu
et al., 1995). Anti-Stat3 polyclonal antibodies (C20X; Santa Cruz Biotech-
nology) were used as blocking antibodies for Stat3 binding identification. For
blocking assays, 1 ml of the concentrated Stat3 antibody was pre-incubated
with nuclear protein for 20 min at room temperature prior to the addition of ra-
diolabeled probe (30 min, 30C) and separated by non-denaturing polyacryl-
amide gel electrophoresis and autoradiographic detection.
Cell Transfection and RNA Interference
MDAH2774 (2.5 3 106) and LN-17 (2.0 3 106) cells were transfected with
siRNAs with the Amaxa Nucleofector (Amaxa) according to the manufacturer’s
protocol. MDAH2774 Cells were transfected with 100 nM siRNA using Amaxa
Solution-L and program A-033. LN-17 cells were transfected with 300 nM
(LN-17) siRNA using Amaxa Solution-R and program T-009. A GFP-expressing
plasmid (Amaxa) was used to determine transfection efficiency. Silencer
GAPDH siRNA, nonsilencing siRNA, silencer validated Jak1 (42841 and 219),
Jak2 siRNAs (607 and 608), and Tyk2 siRNA (399 and 398) were purchased
from Ambion. Cells were plated in a poly-L-Lycine coated 6 well plate (BD
Biosciences) and incubated at 37C/0.5% CO2 for 24 and 48 hr. Cell lysates
were collected for immunoblotting.
Tumor Models
Tumor studies were performed as previously described (Hedvat et al., 2004).
Four to six week old athymic mice were purchased from Taconic Laboratories
and acclimated for at least 3 days prior to tumor implantation. Mice bearing
MDAH2774 xenografts were maintained under specific pathogen-free condi-
tions and were used in compliance with protocols approved by the Institutional
Animal Care and Use Committees of AstraZeneca, which conform to institu-
tional and national regulatory standards on experimental animal usage. All
remaining animal model studies were used in compliance with protocols
approved by the Institutional Animal Care and Use Committees of City of
Hope. Cell lines were subcutaneously implanted in athymic mice for MEF-
Stat3-YFP, DU145, MDA-MB-468, and MDA-MB-468 cells expressing Stat3
shRNA or vector alone and 786-0 cells expressing pRC-vector or pRC-Stat3C
in a 1:1 mixture of Matrigel (BD Biosciences) and culture medium. Cell lines
were subcutaneously implanted in athymic mice with PBS for MDAH2774
cells. Tumor-bearing mice were randomized based on tumor volume prior to
the initiation of treatment, which was initiated when average tumor volume
was at least 65 mm3. AZD1480 was given orally, as indicated in water supple-
mented with 0.5% Hypermellose and 0.1% Tween 80. Tumors were measured
every 3 to 4 days with vernier calipers, and tumor volumes were calculated by
the formula 0.5 3 (larger diameter) 3 (smaller diameter)2.
Statistical Analysis of Tumor Models
Tumor growth inhibition is calculated as 1  T/C. T/C = (DT/DC) 3 100, where
T > 0, or %T/C = (DT/T1) 3 100, where DT < 0. DT is the change of tumor496 Cancer Cell 16, 487–497, December 8, 2009 ª2009 Elsevier Inc.volume in the treatment group, DC is that for the control group, and T1 is
the mean tumor volume at the start of treatment.
p values indicated for animal efficacy studies consisting of two cohorts,
LN-17 cell-line-derived data or CBC data, were derived with a Student’s t
test. Statistical analysis of the MDAH2774 xenograft study was performed
with one-way ANOVA and p values were corrected for multiple comparisons
to control by Dunnett’s method.
SUPPLEMENTAL DATA
Supplemental Data include eight figures and can be found with this article online
at http://www.cell.com/cancer-cell/supplemental/S1535-6108(09)00384-5.
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